Wednesday, 15 August 2018 - 12:14
  • it
  • de
  • en
  • fr

Pathology

Biotech BeiGene ready for listing in Hong Kong

China-based biotech BeiGene, listed in the US Nasdaq, has announced it pursues a listing in the Hong Kong stock market too. According to BeiGene’s management, this second listing should fetch the company at least $903m. The biotech will offer 65…

Worrisome rise in malaria cases: 700,000 victims per year now

The scientific journal Nature has published a long and detailed review about the dramatic increase of malaria cases in the poorest areas of the world, where it is the first cause of death, killing 450,000-700,000 people annually. The most efficient…

New Ebola outbreak seems contained

Good news about Ebola: the World Health Organization has informed that the new outbreak reported in the Democratic Republic of Congo–and specifically in the densely populated city of Mbandaka–seems to have been contained. Since April 1st, physicians have reported as…

NASH sector heats up

Bloomberg yesterday reported that biotech Madrigal Pharmaceuticals  is weighing a sale after some early talks with large pharmaceutical groups. The news has made Madrigal’s shares jump by over 150% in the last month. Madrigal is a biotech based in Pennsylvania,…

Worrisome increase in spread of sexually-transmitted diseases

The spreading rate of sexually-transmitted diseases is worrisomely increasing in the UK. The most recent data demonstrate that syphilis cases have risen by 20% over the last year, while gonorrhea cases by 22%, and experts are particularly worried by a…

Inflammation triggers depression

Depression is nowadays one of the most widespread diseases in the world. Although millions of people suffer from it, its real causes are still unknown. Neuropsychiatrist Edward Bullmore, from the University of Cambridge (UK) has proposed that depression is a…

Brain’s role in diabetes: new approach to insulin regulation

The prestigious journal Science has published today a significant study by a team of scientists led by Kasper Horst, from the Department of Endocrinology and Metabolism, Academic Medical Center of Amsterdam. The study reports data showing the brain’s role in…

Revolutionary theory explaining origin of childhood leukemia

The English scientist Mel Greaves, from the Institute of Cancer Research of London, has formulated an original theory about the onset of childhood leukemia, which has been published in the latest issue of Nature Review Cancer. According to Graves, leukemia…

Anticholinergic drugs may induce dementia

A group of English researchers has published an interesting study funded by the Alzheimer Society, which analyzes the long-term effects of some major drugs in patients. Specifically, the team has assessed drugs for the treatment of major conditions, such as…

New FDA approval for US-based biotech Ultragenyx

The Novato, California-based biotech Ultragenyx yesterday announced, before Wall Street opened, that its investigational therapy Crysvita (burosumab) has obtained the FDA approval for the treatment of X–Linked Hypophosphatemia (XLH), a rare condition. XLH is a serious disease affecting bones, which…

Intercept shows another significant benefit of Ocaliva to people with PCB

New York-based biotech company Intercept Pharmaceuticals keeps momentum: its shares have risen over 15% since the beginning of the month. Intercept yesterday announced in a press release that the Phase III POISE clinical trial has demonstrated that Ocaliva (obeticholic acid)…

GSK announces sale of rare disease therapies to Orchard Therapeutics

GlaxoSmithKline has sold its rare disease therapy portfolio to Orchard Therapeutics in exchange for 20% of shares in the Anglo-American biotech and royalties on profits delivered by Orchard with GSK’s treatments. GSK’s move allows the UK-based company to focus on…

Chinese biotech sector, leader in CAR-T technology

China has clearly acquired an outstanding position in the CAR-T area, with 116 ongoing clinical trials, versus 96 in the US and 15 in Europe. Chinese researchers are obtaining positive results in the treatment of blood cancers considered incurable before…

Rude awakening for immunotherapy sector

Last Friday’s news about the failed Phase III clinical trial with immunotherapy Keytruda in combination with Incyte’s cancer therapy epacadostat not only has wiped $4m from the US biotech’s capitalization over few hours, but has also risen much concern among…

The immunotherapy market

The Financial Times has published  today a very short review about the immunotherapy market. This business is currently dominated by Merck & Co and Bristol-Myers Squibb with blockbusters Keytruda and Opdivo, however these are already facing competition from Roche, Pfizer…

Sanofi seeks to restore leadership in diabetes treatments

Sanofi is trying to restore its leading position in diabetes treatments, like at the time when its insulin Lantus was among blockbusters. The France-based group is now largely focusing on sotagliflozin, which acts as a SGLT-1 and SGLT-2 inhibitor and…

Good news for Teva at last: generic to Lialda launched

Good news are coming from Teva at last: the Israeli-based pharmaceutical group has announced it has launched the generic version of Lialda (mesalamine) 1.2g in the US. Mesalamine is indicated for the treatment of ulcerative colitis, a disorder affecting over…

Good Phase III results for Roche’s Tecentriq

Switzerland-based group Roche yesterday issued a press release announcing that its immunotherapy tecentriq (atezolizumab) has delivered positive results in combination with chemotherapy (carboplatin and Abraxane). The data have been collected during the Phase III IMpower131 clinical trial, conducted on patients…

Celgene signs $150m agreement with Prothena to develop Alzheimer’s drug

Celgene has entered into an agreement with biotech Prothena in order to acquire the rights to three Alzheimer’s drug candidates based on three proteins identified by Prothena. Specifically, under the agreement, the companies will co-develop the drug candidates. Should these…